Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
122M
-
Number of holders
-
15
-
Total 13F shares, excl. options
-
12.5M
-
Shares change
-
-650K
-
Total reported value, excl. options
-
$28.1M
-
Value change
-
-$1.75M
-
Number of buys
-
5
-
Number of sells
-
-6
-
Price
-
$2.25
Significant Holders of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) as of Q2 2021
18 filings reported holding TRVI - Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q2 2021.
Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) has 15 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 12.5M shares
of 122M outstanding shares and own 10.27% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (5.94M shares), TPG Group Holdings (SBS) Advisors, Inc. (4.82M shares), Omega Fund Management, LLC (1.26M shares), VANGUARD GROUP INC (133K shares), RENAISSANCE TECHNOLOGIES LLC (92.6K shares), GEODE CAPITAL MANAGEMENT, LLC (49.1K shares), BlackRock Inc. (44.2K shares), WealthTrust Axiom LLC (39.5K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (34.6K shares), and Alberta Investment Management Corp (25K shares).
This table shows the top 15 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.